The University of Southampton
University of Southampton Institutional Repository

The effects of recombinant human insulin like growth factor-1/insulin like growth factor binding protein 3 administration on lipid and carbohydrate metabolism in recreational athletes

The effects of recombinant human insulin like growth factor-1/insulin like growth factor binding protein 3 administration on lipid and carbohydrate metabolism in recreational athletes
The effects of recombinant human insulin like growth factor-1/insulin like growth factor binding protein 3 administration on lipid and carbohydrate metabolism in recreational athletes
Objective
Previous studies suggested that recombinant human IGF-1 (rhIGF-1) administration affects carbohydrate and lipid metabolism in healthy people and in people with diabetes. This study aimed to determine the effects of rhIGF-1/rhIGF binding protein-3 (rhIGFBP-3) administration on glucose homeostasis and lipid metabolism in healthy recreational athletes.

Design and Setting
Randomized, double-blind, placebo-controlled rhIGF-1/rhIGFBP-3 administration study at Southampton General Hospital, UK.

Participants
56 recreational athletes (30 men, 26 women).

Methods
Participants were randomly assigned to receive placebo, low-dose rhIGF-1/rhIGFBP-3 (30 mg/day) or high-dose rhIGF-1/rhIGFBP-3 (60 mg/day) for 28 days. The following variables were measured before and immediately after the treatment period: fasting lipids, glucose, insulin, C-peptide and glycated haemoglobin. The homeostatic model assessment (HOMA-IR) was used to estimate insulin sensitivity and indirect calorimetry to assess substrate oxidation rates. The general linear model approach was used to compare treatment group changes with the placebo group.

Results
Compared with the placebo group, there was a significant reduction in fasting triglycerides in participants treated with high-dose rhIGF-1/rhIGFBP-3 (p = .030), but not in the low-dose group (p = .390). In women, but not in men, there were significant increases in total cholesterol (p = .003), HDL cholesterol (p = .001) and LDL cholesterol (p = .008). These lipid changes were associated with reduced fasting insulin (p = .010), C-peptide (p = .001) and HOMA-IR (p = .018) in women and reduced C-peptide (p = .046) in men.

Conclusions
rhIGF-1/rhIGFBP-3 administration for 28 days reduced insulin concentration, improved insulin sensitivity and had significant effects on lipid profile including decreased fasting triglycerides.
0300-0664
551-562
Guha, Nishan.
6fc9a034-0ca9-45f2-9b61-363412919069
Nevitt, Simon P.
c3b28987-b9cb-4c9a-96d8-dd543bbe482c
Francis, Michael
93112f9d-8b2b-454b-ab6f-7f0d286f09e0
Bohning, Walailuck
4d2abe7f-ae5e-4df1-903f-086366664de6
Bohning, Dankmar
1df635d4-e3dc-44d0-b61d-5fd11f6434e1
Sonksen, Peter
a3249c5c-0903-472d-8054-6cffde597d44
Holt, Richard
d54202e1-fcf6-4a17-a320-9f32d7024393
Guha, Nishan.
6fc9a034-0ca9-45f2-9b61-363412919069
Nevitt, Simon P.
c3b28987-b9cb-4c9a-96d8-dd543bbe482c
Francis, Michael
93112f9d-8b2b-454b-ab6f-7f0d286f09e0
Bohning, Walailuck
4d2abe7f-ae5e-4df1-903f-086366664de6
Bohning, Dankmar
1df635d4-e3dc-44d0-b61d-5fd11f6434e1
Sonksen, Peter
a3249c5c-0903-472d-8054-6cffde597d44
Holt, Richard
d54202e1-fcf6-4a17-a320-9f32d7024393

Guha, Nishan., Nevitt, Simon P., Francis, Michael, Bohning, Walailuck, Bohning, Dankmar, Sonksen, Peter and Holt, Richard (2021) The effects of recombinant human insulin like growth factor-1/insulin like growth factor binding protein 3 administration on lipid and carbohydrate metabolism in recreational athletes. Clinical Endocrinology, 94 (4), 551-562. (doi:10.1111/cen.14370).

Record type: Article

Abstract

Objective
Previous studies suggested that recombinant human IGF-1 (rhIGF-1) administration affects carbohydrate and lipid metabolism in healthy people and in people with diabetes. This study aimed to determine the effects of rhIGF-1/rhIGF binding protein-3 (rhIGFBP-3) administration on glucose homeostasis and lipid metabolism in healthy recreational athletes.

Design and Setting
Randomized, double-blind, placebo-controlled rhIGF-1/rhIGFBP-3 administration study at Southampton General Hospital, UK.

Participants
56 recreational athletes (30 men, 26 women).

Methods
Participants were randomly assigned to receive placebo, low-dose rhIGF-1/rhIGFBP-3 (30 mg/day) or high-dose rhIGF-1/rhIGFBP-3 (60 mg/day) for 28 days. The following variables were measured before and immediately after the treatment period: fasting lipids, glucose, insulin, C-peptide and glycated haemoglobin. The homeostatic model assessment (HOMA-IR) was used to estimate insulin sensitivity and indirect calorimetry to assess substrate oxidation rates. The general linear model approach was used to compare treatment group changes with the placebo group.

Results
Compared with the placebo group, there was a significant reduction in fasting triglycerides in participants treated with high-dose rhIGF-1/rhIGFBP-3 (p = .030), but not in the low-dose group (p = .390). In women, but not in men, there were significant increases in total cholesterol (p = .003), HDL cholesterol (p = .001) and LDL cholesterol (p = .008). These lipid changes were associated with reduced fasting insulin (p = .010), C-peptide (p = .001) and HOMA-IR (p = .018) in women and reduced C-peptide (p = .046) in men.

Conclusions
rhIGF-1/rhIGFBP-3 administration for 28 days reduced insulin concentration, improved insulin sensitivity and had significant effects on lipid profile including decreased fasting triglycerides.

Text
NG_IGF_Glucose_Lipids_07Oct2020_NoMarkup - Accepted Manuscript
Download (160kB)
Slideshow
Figure 1A-1F - Accepted Manuscript
Download (583kB)
Slideshow
Figure 2A-2E - Accepted Manuscript
Download (477kB)

More information

Accepted/In Press date: 11 October 2020
e-pub ahead of print date: 29 November 2020
Published date: 19 March 2021

Identifiers

Local EPrints ID: 445007
URI: http://eprints.soton.ac.uk/id/eprint/445007
ISSN: 0300-0664
PURE UUID: 8cc1c282-d231-4fe8-b713-501f9afc04e4
ORCID for Dankmar Bohning: ORCID iD orcid.org/0000-0003-0638-7106
ORCID for Richard Holt: ORCID iD orcid.org/0000-0001-8911-6744

Catalogue record

Date deposited: 18 Nov 2020 13:16
Last modified: 17 Mar 2024 06:00

Export record

Altmetrics

Contributors

Author: Nishan. Guha
Author: Simon P. Nevitt
Author: Michael Francis
Author: Walailuck Bohning
Author: Dankmar Bohning ORCID iD
Author: Peter Sonksen
Author: Richard Holt ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×